Double whammy sours mood at Antios Therapeutics

26 May 2022
research_biotech_lab_computer_results_big

Antios Therapeutics has been given the cold shoulder by erstwhile development partner Assembly Biosciences (Nasdaq: ASMB), after a clinical hold was placed on its hepatitis B program.

Both firms are working towards finding a curative therapy for hepatitis B, a potentially life-threatening liver infection caused by a virus (HBV).

The short-lived deal, inked in October 2021, saw the firms working together to evaluate a combination of Antios’ lead candidate ATI-2173 and vebicorvir, an HBV core inhibitor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology